The therapeutic approach to breast cancer necessitates a personalized strategy that accounts for the patient’s unique profile, encompassing the tumor’s biological attributes, genomic expression signatures, estrogen and progesterone receptor status, HER2 amplification, tumor microenvironmental dynamics, the patient’s genetic predispositions, and lifestyle factors (1). This evidence concerns the gene ERBB2 and neoplasm.